RhumbLine Advisers
ABVX

RhumbLine Advisers’s Abivax ABVX Stock Holding History

RhumbLine Advisers’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Buy
2,157
+716
+50% +$81K ﹤0.01% 3099
2026
Q1 		$160K Sell
1,441
-277
-16% -$32.8K ﹤0.01% 3223
2025
Q4 		$232K Buy
1,718
+697
+68% +$76K ﹤0.01% 3107
2025
Q3 		$86.7K Buy
1,021
+40
+4% +$2.45K ﹤0.01% 3561
2025
Q2 		$7.5K Buy
981
+243
+33% +$1.58K ﹤0.01% 3894
2025
Q1 		$4.61K Buy
738
+32
+5% +$217 ﹤0.01% 3915
2024
Q4 		$5.17K Buy
706
+22
+3% +$203 ﹤0.01% 3951
2024
Q3 		$7.88K Buy
684
+90
+15% +$1.08K ﹤0.01% 3920
2024
Q2 		$7.85K Buy
594
+395
+198% +$5.65K ﹤0.01% 4018
2024
Q1 		$2.85K Buy
+199
New +$2.57K ﹤0.01% 4051

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's ABVX Position: Q2 2026 in Review

RhumbLine Advisers increased its Abivax (ABVX) stake by 50% in Q2 2026, buying an estimated $81K and bringing the position to 2,157 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #3099.

RhumbLine Advisers first reported a position in ABVX in Q1 2024 and has held it in 10 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • RhumbLine Advisers held 2,157 shares of Abivax worth $287K as of Q2 2026.
  • RhumbLine Advisers bought 716 Abivax shares in Q2 2026, an estimated $81K.
  • Abivax made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3099 holding.
  • RhumbLine Advisers first reported a position in Abivax in Q1 2024 and has held it in 10 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.